Journal: International journal of radiation oncology, biology, physics
Article Title: Targeting Phosphatidylinositol 4-Kinase III? for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent.
PMID/MRN: 27788957
Publication Date: 2016-Nov-15
Abstract:
To investigate which isotype of phosphatidylinositol 4-kinase (PI4K) may affect radiosensitivity and examine whether anti-hepatitis C viral (HCV) agents, some of which have been shown to inhibit PI4K III? activity, could be repositioned as a radiosensitizer in human cancer cells.
U251, BT474, and HepG2 cell lines and normal human astrocyte were used. Ribonucleic acid interference, clonogenic assays, Western blotting, immunofluorescence, annexin V assay, lysotracker staining, and ?-galactosidase assay were performed.
Of the 4 PI4K isotypes, specific inhibition of III? increased radiosensitivity. For pharmacologic inhibition of PI4K III?, we screened 9 anti-HCV agents by half-maximal inhibitory concentration assay. Simeprevir was selected, and its inhibition of PI4K III? activity was confirmed. Combination of simeprevir treatment and radiation significantly attenuated expression of phospho-phospho-PKC and phospho-Akt and increased radiation-induced cell death in tested cell lines. Pretreatment with simeprevir prolonged ?H2AX foci formation and down-regulation of phospho-DNA-PKcs, indicating impairment of nonhomologous end-joining repair. Cells pretreated with simeprevir exhibited mixed modes of cell death, including apoptosis and autophagy.
These data demonstrate that targeting PI4K III? using an anti-HCV agent is a viable approach to enhance the therapeutic efficacy of radiation therapy in various human cancers, such as glioma, breast, and hepatocellular carcinoma.
Copyright © 2016 Elsevier Inc. All rights reserved.